← NEUROCRINE BIOSCIENCES INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $15.0m |
$161.6m
+977.51%
|
$451.2m
+179.19%
|
$788.1m
+74.65%
|
$1.0b
+32.71%
|
$1.1b
+8.38%
|
$1.5b
+31.34%
|
$1.9b
+26.76%
|
$2.4b
+24.81%
|
$2.9b
+21.45%
|
$3.4b
+17.95%
|
|
| Cost of Revenue | $0 | $1.3m |
$4.9m
+289.87%
|
$361.7m
+7299.10%
|
$10.1m
-97.21%
|
$14.3m
+41.58%
|
$23.2m
+62.24%
|
$39.7m
+71.12%
|
$34.0m
-14.36%
|
$52.1m
+53.24%
|
$70.5m
+35.32%
|
|
| Gross Profit (Calculated) (derived) | $15.0m |
$160.4m
+969.15%
|
$446.4m
+178.32%
|
$426.3m
-4.48%
|
$1.0b
+142.95%
|
$1.1b
+8.05%
|
$1.5b
+30.94%
|
$1.8b
+26.06%
|
$2.3b
+25.65%
|
$2.8b
+20.98%
|
— | |
| Research and Development Expense | $94.3m | $121.8m | $160.5m | — | — | — | — | — | — | — | $1.1b | |
| General and Administrative Expense | $68.1m | $169.9m | $248.9m | $354.1m | $433.3m | $583.3m | $752.7m | $887.6m | $1.0b | $1.2b | — | |
| Amortization of Intangible Assets | — | — | — | — | — | — | $500k | $3.5m | $3.6m | $4.1m | — | |
| Operating Expenses | $162.4m | $293.0m | $414.3m | $715.8m | $882.9m | $1.0b | — | — | — | — | $2.6b | |
| Operating Income (Loss) | ($147.4m) |
($131.4m)
+10.86%
|
$36.9m
+128.09%
|
$72.3m
+95.92%
|
$163.0m
+125.50%
|
$102.5m
-37.12%
|
$249.0m
+142.93%
|
$250.9m
+0.76%
|
$570.5m
+127.38%
|
$619.1m
+8.52%
|
$806.2m
+30.22%
|
|
| Interest Expense | — | $19.5m | $30.5m | $32.0m | $32.8m | $25.8m | $7.1m | $4.6m | — | — | $126.6m | |
| Investment Income, Net | $2.8m | $6.2m | — | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | $13k | ($20k) | — | — | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | $218.0m | $409.2m | $597.5m | $845.2m | $940.2m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | $21.8m | $46.5m | $106.7m | $101.4m | $213.9m | $332.1m | $486.0m | $705.4m | $940.2m | |
| Current Income Tax Expense (Benefit) | — | — | $730k | $9.5m | $10.1m | $6.3m | $37.4m | $143.1m | $267.7m | $62.6m | $234.7m | |
| Income Tax Expense (Benefit) | $0 | $0 | $730k | $9.5m | ($300.6m) | $11.8m | $59.4m | $82.4m | $144.7m | $226.8m | $234.7m | |
| Net Income (Loss) Attributable to Parent | ($141.1m) |
($142.5m)
-1.03%
|
$21.1m
+114.81%
|
$37.0m
+75.32%
|
$407.3m
+1000.45%
|
$89.6m
-78.00%
|
$154.5m
+72.43%
|
$249.7m
+61.62%
|
$341.3m
+36.68%
|
$478.6m
+40.23%
|
$705.5m
+47.41%
|
|
| Earnings Per Share, Basic | ($1.63) | ($1.62) | $0.23 | $0.40 | $4.38 | $0.95 | $1.61 | $2.56 | $3.40 | $4.81 | $7.05 | |
| Earnings Per Share, Diluted | ($1.63) | ($1.62) | $0.22 | $0.39 | $4.16 | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 | $6.84 | |
| Weighted Average Number of Shares Outstanding, Basic | 86.7m | 88.1m | 90.2m | 91.6m | 93.1m | 94.6m | 95.8m | 97.7m | 100.4m | 99.5m | 100.2m | |
| Weighted Average Number of Shares Outstanding, Diluted | 86.7m | 88.1m | 95.4m | 95.7m | 97.8m | 97.9m | 98.9m | 101.0m | 103.7m | 102.5m | 103.5m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | — | — | — | — | — | — | $1.2b | $1.6b | $1.8b | $2.2b | — | |
| Realized Investment Gains (Losses) | $0 | — | — | — | — | — | — | — | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.